Nectar Lifesciences Ltd. (IN:NECLIFE)
:NECLIFE
Want to see IN:NECLIFE full AI Analyst Report?
Total Valuation
Nectar Lifesciences Ltd. has a market cap or net worth of ₹2.27B. The enterprise value is ₹1.23B.
Market Cap₹2.27B
Enterprise Value₹1.23B
Share Statistics
Nectar Lifesciences Ltd. has 194,260,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding194,260,970
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Nectar Lifesciences Ltd.’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -6.51%.
Return on Equity (ROE)-0.50
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-6.51%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee11.92K
Profits Per Employee-4.68M
Employee Count1,686
Asset Turnover<0.01
Inventory Turnover204.71
Valuation Ratios
The current PE Ratio of Nectar Lifesciences Ltd. is ―. Nectar Lifesciences Ltd.’s PEG ratio is -0.00357.
PE Ratio―
PS Ratio97.56
PB Ratio0.34
Price to Fair Value0.34
Price to FCF-0.54
Price to Operating Cash Flow1.53
PEG Ratio-0.00357
Income Statement
In the last 12 months, Nectar Lifesciences Ltd. had revenue of 20.11M and earned -2.93B in profits. Earnings per share was -14.57.
Revenue20.11M
Gross Profit-590.34M
Operating Income-590.34M
Pretax Income-878.79M
Net Income-2.93B
EBITDA-289.51M
Earnings Per Share (EPS)-14.57
Cash Flow
In the last 12 months, operating cash flow was 1.53B and capital expenditures -89.31M, giving a free cash flow of 1.44B billion.
Operating Cash Flow1.53B
Free Cash Flow1.44B
Free Cash Flow per Share7.40
Dividends & Yields
Nectar Lifesciences Ltd. pays an annual dividend of ₹4.319, resulting in a dividend yield of ―
Dividend Per Share₹4.319
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change-45.03%
50-Day Moving Average12.14
200-Day Moving Average14.31
Relative Strength Index (RSI)50.49
Average Volume (3m)34.32K
Important Dates
Nectar Lifesciences Ltd. upcoming earnings date is Aug 19, 2026, TBA (Confirmed).
Last Earnings DateMay 30, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Nectar Lifesciences Ltd. as a current ratio of 8.40, with Debt / Equity ratio of 0.00%
Current Ratio8.40
Quick Ratio8.39
Debt to Market Cap0.00
Net Debt to EBITDA3.87
Interest Coverage Ratio-1.63
Taxes
In the past 12 months, Nectar Lifesciences Ltd. has paid -305.32M in taxes.
Income Tax-305.32M
Effective Tax Rate0.35
Enterprise Valuation
Nectar Lifesciences Ltd. EV to EBITDA ratio is -2.90, with an EV/FCF ratio of -0.23.
EV to Sales41.78
EV to EBITDA-2.90
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.24
Balance Sheet
Nectar Lifesciences Ltd. has ₹139.72M in cash and marketable securities with ₹4.59B in debt, giving a net cash position of -₹4.45B billion.
Cash & Marketable Securities₹139.72M
Total Debt₹4.59B
Net Cash-₹4.45B
Net Cash Per Share-₹22.90
Tangible Book Value Per Share₹28.92
Margins
Gross margin is -13.51%, with operating margin of -2936.29%, and net profit margin of -14568.07%.
Gross Margin-13.51%
Operating Margin-2936.29%
Pretax Margin-4371.00%
Net Profit Margin-14568.07%
EBITDA Margin-1439.97%
EBIT Margin-2574.17%
Analyst Forecast
The average price target for Nectar Lifesciences Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-82.81%
EPS Growth Forecast-164.57%